Cost-Effectiveness of Second-Line Empagliflozin versus Liraglutide for Type 2 Diabetes in the United States. Reifsnider OS, Pimple P, Brand S, Bergrath Washington E, et al. Diabetes Obes Metab 2021 Dec 14. doi: 10.1111/dom.14625.

Read + Share

Amedeo Smart

Independent Medical Education

Reifsnider OS, Pimple P, Brand S, Bergrath Washington E, et al. Cost-Effectiveness of Second-Line Empagliflozin versus Liraglutide for Type 2 Diabetes in the United States. Diabetes Obes Metab 2021 Dec 14. doi: 10.1111/dom.14625.
PMID: 34910356